HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TMDX
TransMedics Group, Inc.
TMDX's fundamentals are mixed, but it looks cheap: trading at 25x earnings, less than half its usual 59x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TMDX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Stable | |
| Strong |
TMDX's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TMDX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 21x | $75.93 | -17% |
| Current | 25x | $92.00 | — |
| Forward | 41x | $92.00 | — |
| Fair | 59x | $217 | +136% |
| Expensive | 91x | $335 | +264% |
Historical ranges are pointers, not guarantees.
TMDX's PE is in its cheap range at 25x. On analysts' estimates for next year's earnings, today's price would be 41x.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TMDX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for TMDX, but weaker profitability. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TMDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.22 | -39% |
| Q3 2026 | $3.66 | +48% |
| Q2 2026 | $3.86 | +100% |
| Q1 2026 | $4.37 | +221% |
| Q4 2025 | $4.87 | +382% |
| Q3 2025 | $2.47 | +163% |
| Q2 2025 | $1.93 | +4725% |
| Q1 2025 | $1.36 | +$1.70 |
| Q4 2024 | $1.01 | +$1.78 |
TMDX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TMDX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TMDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $203M | +41% |
| Q2 2026 | $189.9M | +21% |
| Q1 2026 | $173.9M | +21% |
| Q4 2025 | $160.8M | +32% |
| Q3 2025 | $143.8M | +32% |
| Q2 2025 | $157.4M | +38% |
| Q1 2025 | $143.5M | +48% |
| Q4 2024 | $121.6M | +50% |
TMDX's revenue has grown year over year for 20 quarters in a row: $203M last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -2.3 points |
| Q2 2026 | 13% | -11 points |
| Q1 2026 | 7.6% | -12 points |
| Q4 2025 | 13% | +6.1 points |
| Q3 2025 | 16% | +13 points |
| Q2 2025 | 23% | +12 points |
| Q1 2025 | 19% | +6.3 points |
| Q4 2024 | 7.1% | +3.9 points |
TMDX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TMDX on cash flow, with more consistent year-over-year improvement.
TMDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $27.6M | -55% |
| Q2 2026 | $10.2M | -88% |
| Q1 2026 | -$12.1M | +$17.8M |
| Q4 2025 | $19M | +214% |
| Q3 2025 | $61.9M | +$103.3M |
| Q2 2025 | $82.5M | +4122% |
| Q1 2025 | -$29.9M | +$17.7M |
| Q4 2024 | $6.1M | +$39.6M |
TMDX has burned cash in most quarters: $45M over the past year, down 63% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TMDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TMDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +124K shares |
| 1 year | +0.2% | +85.2K shares |
| 3 years | +25% | +8.2M shares |
| 5 years | +47% | +13.1M shares |
| Available history | +92% | +19.6M shares |
TMDX has 41M diluted shares, about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TMDX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.5x | Net Cash |
| Q2 2026 | -3.8x | Net Cash |
| Q1 2026 | -3.5x | Net Cash |
| Q4 2025 | -3.5x | Net Cash |
| Q3 2025 | -3.8x | Net Cash |
| Q2 2025 | -4.0x | Net Cash |
| Q1 2025 | -4.2x | Net Cash |
| Q4 2024 | -5.9x | Net Cash |
TMDX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TMDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 54.9 | Neutral |
TMDX's weekly RSI is 55 (neutral) and its Stochastic is 55 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TMDX PE vs Healthcare Sector
| Metric | TMDX | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 2.7% below |
| PE % | 29 | 29 | Same percentile |
TMDX is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TMDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $78.8 | 17% above |
| 20 week MA | $80.4 | 14% above |
| 50 week MA | $98.1 | 6.2% below |
| 100 week MA | $99.8 | 7.9% below |
| 200 week MA | $96.2 | 4.4% below |
TMDX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TMDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.6 | $18.8 | +1% |
| 2021 | $18.8 | $21.0 | +12% |
| 2022 | $21.0 | $59.5 | +183% |
| 2023 | $59.5 | $78.9 | +33% |
| 2024 | $78.9 | $61.0 | -23% |
| 2025 | $61.0 | $124.2 | +104% |
| 2026 YTD | $124.2 | $92.0 | -26% |
TMDX has the edge over HIMS on returns for 2026, with the stronger performance.